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Abstract
Background—The insulin/ growth factor 1 (IGF-1) signaling pathway promotes adipocyte
differentiation and therefore insulin sensitivity via suppression of Necdin expression, which
represses PPAR γ promoter activity via interaction with E2F4 in mouse adipocytes.
Objectives—The aim of this study was to test the hypothesis that this pathway represents one of
the mechanisms by which Roux-en-Y gastric bypass surgery (RYGB) induces resolution of insulin
resistance.
Methods—Clinical samples were collected and key biomarkers were measured in order to test
the hypothesis that the IGF-1 pathway represents one of the mechanisms by which RYGB induces
resolution of insulin resistance in obese individuals.
Results—Free IGF-1 levels were significantly higher in the post-RYGB patients as compared to
pre-RYGB obese patients (2.55±1.54 vs. 1.32±0.65 mcg/l, p=0.03) and similar to normal weight
controls (2.54±1.27 mcg/l). Necdin and E2F4 gene expression in the adipose tissue were
significantly down-regulated after GBS when compared with obese and were similar to levels
observed in the lean controls. In human mature adipocytes cultured in vitro, treatment with des-
IGF-1 induced down-regulation of Necdin and E2F4 gene expression in a dose-dependent manner
(p=0.01).
Conclusion—After RYGB, the insulin/IGF-1 signaling pathway is activated and could account
for the observed decrease in expression of Necdin, which represses PPAR γ promoter activity via
interaction with E2F4. This could represent one of the mechanisms that induce resolution of
insulin resistance status following RYGB.
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Introduction
Adipose tissue plays an important role in modulating insulin sensitivity through production
of metabolites, such as free fatty acids, and in its role as an endocrine organ producing a
variety of adipokines(1). In obesity, abnormal adipogenesis impairs insulin action and
predisposes to type 2 diabetes mellitus (T2DM) In fact, the majority of patients with T2DM
are obese or overweight(2). In obese patients with T2DM, significant weight loss results in
amelioration or resolution of their insulin resistance status. This increased insulin sensitivity
results from insulin mediated enhancement of glucose uptake and from hepatic glucose
output suppression(3).
Previous studies have shown that Roux-en-Y gastric bypass (RYGB) is very effective in
inducing remission of T2DM in morbidly obese patients(3). Thus, one strategy for treating
class II and III obese patients with T2DM who are not adequately treated by medical
intervention is interventional surgery(4). Defining the underlying mechanisms that cause the
improvement after RYGB may potentially uncover novel molecular targets for non-surgical
interventions. Towards this end, multiple studies have focused on identifying variables
predictive of remission of T2DM following RYGB, including pre-operative BMI, HbA1c,
visceral adiposity and duration of the diabetic status(5–6).
Few studies have examined the role of insulin-like growth factor 1 (IGF-1) as a mediator of
the anti-diabetic effects of bariatric surgery. Obesity is associated with the impairment of
normal growth hormone (GH) secretion, which regulates the production of IGF-1. IGF-1
levels significantly increase after surgical induced weight loss. Engström et al.(7)
investigated a well-characterized group of severely obese patients before and after RYGB.
Serum GH and IGF-1 significantly increased 12 months after RYGB. It is well known that
IGF-1 promotes adipocyte differentiation and thus increases insulin sensitivity and alters
adipocyte differentiation through intricate signaling pathways(8).IGF1 binding to its cell
surface receptor stimulates phosphorylation of several intracellular IGF1 receptor substrates
(IRSs) that lead to activate of the PI(3)K and the MAP kinase pathways. These insulin
receptor substrate proteins regulate Necdin-E2F4 interaction that represses peroxisome-
proliferator-activated receptor gamma (PPAR γ) transcription via a cyclic AMP response
element binding protein (CREB)-dependent pathway(8). PPAR γ has been proven crucial in
the control of terminal adipocyte differentiation, and is the target for insulin-sensitizing
thiazolidinediones (TZDs), which are used clinically for treatment of T2DM(9–10). Goldfine
and others have demonstrated that changes in gene expression of E2F4 and Necdin after
treatment with the selective PPARγ agonist rosiglitazone are linked to transformed
adipocyte differentiation(11).
Based on the evidences that the IGF-1 signaling pathway promotes adipocyte differentiation
and therefore insulin sensitivity, we hypothesized that in obese patients RYGB induces
activation of the insulin/IGF-1 signaling pathway that suppresses the expression of Necdin,
which represses PPAR γ promoter activity via interaction with E2F4. The aim of this study
was to test the hypothesis that this pathway represents one of the mechanisms by which
RYGB induces resolution of insulin resistance.
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We carried out a prospective case-control study where two experimental groups (groups 1
and 2) were compared to a control group (group 3). Additional details regarding the three
subject groups are included below:
Group 1: Non-obese subjects status post-RYGB (with a least 12 months follow up)
undergoing an elective abdominal surgical procedure (e.g. cholecystectomy, abdominal wall
hernia repair, and/or abdominoplasty; Group 2: Diabetic subjects with class II and III
obesity undergoing RYGB; Group 3: Non-obese diabetic individuals (body mass index
(BMI) 20–29) control subjects requiring an elective abdominal surgery. The study was
approved by the institutional review board, and an informed, written consent was obtained
from all subjects prior to participation. The study employed the following exclusion criteria:
diagnosis of neoplastic disease, inflammatory bowel disease, acute cholecystitis, and
pregnancy.
Tissue sample preparation for recombinant extraction and quantitative RT-PCR
During the surgical procedure, two 0.5-cm3 biopsies of abdominal subcutaneous and intra-
abdominal omental fat tissue were obtained. The tissue samples were washed in PBS
solution and then soaked in RNA later preservative solution (Qiagen, Courtaboeuf, France)
and stored at −80°C until analysis.
RNA extraction and quantitative RT-PCR
Total RNA was extracted from paired subcutaneous (SC) and omentum (OM) adipose tissue
(100 mg tissue) using RNeasy Lipid Tissue Kit with an added treatment to remove genomic
DNA using RNase-free DNase (Qiagen Inc., Valencia, CA). cDNA synthesis was carried
out using SuperScript™ III Reverse Transcriptase (Invitrogen Corp., Carlsbad, CA) in the
presence of random hexamers (Advantage; Clontech). Necdin and E2F4 gene expression
were studied by quantitative, real time RT-PCR using the specific protocol for the iCycler
iQ Detection System (BioRad, Hercules, CA, USA) with SYBR green fluorophore. The
specificity of each amplification product was confirmed by melting curve profiles and
agarose gel electrophoresis. All samples were run in duplicate and values averaged. The
GAPDH gene was used as internal control to normalize the PCR reactions for the amount of
RNA added. The data were processed using Gene Expression Analysis Software (Bio-Rad
Life Science, Hercules, CA).
The following primers were designed and used for human Necdin Accession No.
NM_002487.2 forward: 5'-TGTGGTACGTGCTGGTCAAGG-3' and reverse: 5'-
GGCGAGGATGAGGCTGGTG-3'; human E2F4 (Accession No.AF 527540) forward: 5'-
GCAGACCCCACAGGTGTTTT-3' and reverse: 5'-GACCACTCACACTCTTCAGG-3';
human GAPDH(Accession No.NM_002046) forward: 5'CCCATGT
TCGTCATGGGTGT-3' and reverse: 5' TGGTCATGAGGTCCTTCCACGATA-3'. The
PCR primer sequence for Necdin and E2F4 and GAPDH was chosen based on the sequences
available in GenBank (www.ncbi.nlm.nih.gov/Genbank).
IGF1 determinations by high-sensitivity enzymatic assay
A fasting blood sample was also obtained from each subject immediately before the
induction of general anesthesia, immediately spun in a refrigerated (4°C) centrifuge at 3,000
rpm for 10 minutes and stored at – 80° C until analyzed. The extracted plasma was used for
IGF1 determinations by high-sensitivity enzymatic assay (Active Non Extraction IGF-I
IRMA, DSL-2800, Diagnostic Systems Laboratories, Inc.).
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Cell culture and differentiation
Cryopreserved human subcutaneous adipose stem cells (hASCs) purchased from Zen-Bio,
(Zen-Bio Inc., RTP, NC) were maintained and differentiated according to the supplier's
specifications. Differentiated adipocytes maintained in AM-1 medium (Zen- Bio Inc., RTP,
NC) were exposed for 24 hours to 5, 10 and 100 ng/ml of des-(1–3)-IGF-I (des-IGF-I)
(Diagnostic System Laboratories), then harvested by Trizol reagent (Invitrogen Corp.,
Carlsbad, CA). Des-IGF-1 was used in these experiments to avoid interactions with IGF
binding proteins that normally sequester circulating IGF-1.
Western blot analysis
Whole-cell lysates were prepared using RIPA-Lysis buffer supplemented with protease
(Roche Applied Science, Indianapolis, IN) and phosphate inhibitor cocktails (Sigma-Aldrich
Corp., St. Louis, MO). The lysates were resolved on 4–12% Bis-Tris-HCL buffered
polyacrylamide gels (Invitrogen Corp., Carlsbad, CA) and transferred to polyvinylidene
difluoride membranes. These membranes were blocked for an hour with 5% non-fat milk in
TTBS buffer. Primary antibodies were diluted in 5% non-fat milk Membranes were
incubated with a primary antibody for 2 h, after 1 h of blocking in PBS with 0.05% Tween
20 and 5% dry milk, and with primary antibodies for 1 h at room temperature.
Antibodies to Necdin NC243 (ABCAM) and anti-E2F4 (Santa Cruz Biotechnology) were
used at 1:1000 and 1:200, respectively. Blots were incubated with horseradish peroxidase-
conjugated anti-rabbit IgG (Cell Signaling Technologies) and visualized using
chemiluminescence (Western Lightning ECL - PerkinElmer)
Statistical Analysis
Values are presented as the means ± S.D., unless indicated otherwise. Data were analyzed
by GraphPad Prism (Graphpad Software, La Jolla, CA). One way ANOVA (with
Bonferroni's multiple t test for post hoc analysis), paired or unpaired student's test were used
for groups comparison as appropriate. Statistical significance was assumed for p value
<0.05.
Results
A total of twenty six patients were included in this study as shown in Table 1. There were no
significant differences in term of mean age and sex distribution in the three groups. As
shown in Figure 1, in the post-RYGB group free IGF-1 levels were significantly higher than
the pre-RYGB obese patients (2.55±1.54 vs. 1.32±0.65 mcg/l, p=0.03) and similar to non-
obese controls (2.54±1.27 mcg/l).
Necdin and E2F4 expression levels were measured in RNA obtained from subcutaneous and
omental fat tissue samples. As shown in Figure 2, in the post-RYGB Necdin and E2F4 gene
expressions were found to be significantly lower than in the obese group and similar to non -
obese controls. Moreover, this significant change was observed in both the subcutaneous
and omental fat tissue samples.
Studies in cultured differentiated adipocytes were consistent with results seen in adipose
biopsies. Differentiated adipocytes were exposed for 24 hours to 5, 10 and 100 ng/ml des-
IGF-I followed by RNA analysis by Q-PCR. As shown in Figure 3, treatment of
differentiated cultured adipocytes with increasing doses des-IGF-1 down-regulated Necdin
and E2F4 gene expression in a dose-dependent manner (p=0.01 for E2F4). These changes in
gene expressions were confirmed at the protein level by Western blot analysis.
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In our study, we have measured key regulators of insulin sensitivity in human plasma and
adipose tissue samples following RYGB. Specifically, we focused on the role of IGF-1 and
its downstream signaling in adipogenesis process because these pathways have previously
been shown to play key roles in insulin sensitivity. A previous animal study determined that
the IGF-1 signaling pathway promotes adipocyte differentiation and therefore insulin
sensitivity via suppression of Necdin expression, which represses PPAR γ promoter activity
via interaction with E2F4(8). The aim of this study was to test the hypothesis that this
pathway represents one of the mechanisms by which RYGB induces resolution of insulin
resistance in obese patients. The changes we observed suggested Necdin-E2F4 interaction as
one of the mediator for change in insulin sensitivity observed after RYGB. In specific, we
propose a model whereby RYGB activates the insulin/IGF-1 signaling pathway which in
turn up-regulates adipocyte differentiation via a Necdin-E2F4 signaling cascade in
adipocytes. Our model is supported by the following observations: 1) Free IGF1 protein
levels were significantly lower in obese diabetic patients versus lean counterparts; 2) Free
IGF1 protein levels in obese patients increased to levels seen in the lean control population
after RYGB; 3) Necdin and E2F4 mRNA levels were downregulated in subcutaneous and
omental adipose cells following RYGB; and 4) in cultured human adipocytes, des-IGF-1
down-regulated Necdin and E2F4 gene expression in a dose-dependent manner. Other
investigators have also observed improvements in glucose metabolism and increase in IGF-1
after RYGB(7). These studies have focused on the fact that IGF1 stimulates production of an
increased number of adipocyte precursor cells(7, 12).
Some of the conflicting results regarding IGF-1 levels in the literature may be due to
differences in measuring free versus total IGF-1. One study reported that total IGF-1
concentrations were not significantly different between the obese and normal controls,
despite GH hyposecretion in obesity(13). But this same study also found that free IGF-1
concentrations were higher in obese subjects versus normal controls. Variations in total
IGF-1 have also been seen to vary with factors such as ethnicity and age. For example,
Caucasians who were obese in early childhood (increased BMI at age 21) had significantly
lower total IGF1 levels compared to African Americans for those who were obese in early
adulthood(14). In another study, total IGF-I was found to be significantly higher in lean
adolescents than in obese adolescents, whereas basal insulin was elevated in obese
adolescents compared to levels in both groups of lean subjects(15). Though some studies
have negatively correlated total IGF-I with obesity and intra-abdominal fat mass(16,17), the
observations in obese subjects are not consistent(18). Circulating IGF-I interacts with IGF1
Binding Protein (IGFBP-1), and these together could be important determinants of glucose
homoeostasis(19). For example, depressed levels of IGFBP-1 in obese individuals may affect
levels of free IGF-1 bioactivity as well as its feedback regulation of GH secretion(20).
Further studies will be needed to correlate free IGF-1 and IGFBP-1 after RYGB.
We carried out experiments to directly support the association between IGF1 and Necdin-
E2F4 in differentiating human adipocytes. Our analysis showed that in human mature
adipocytes, treatment with des-IGF-1 induces down regulation of Necdin and E2F4 gene
expression in a dose-dependent manner. Our data are consistent with data reported by Tseng
et al(8) after treatment of cultured adipocytes from mice. Necdin has been reported to act
upstream of other regulators of adipogenesis. For example, knockdown of Necdin
expression decreases expression of the adipogenesis inhibitors, Pref-1 and Wnt10a, this
restoring adipocyte differentiation. Additionally, Necdin has been shown to cooperate with
the E2F4 family transcription factors that regulate PPARγ expression. Other studies have
shown that IGF1 increases differentiation of cultured 3T3-L1 cells and pre-
adipocytes(12, 16, 17).
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Our data suggested that activation of the insulin/IGF-1 signaling pathway after RYGB
suppresses expression of Necdin, which represses PPAR promoter activity via interaction
with E2F4. This study highlights this pathway as one of the mechanisms mediating the
resolution of insulin resistance observed after RYGB. However, it is important to underscore
that the changes we observed can be explained by the weight loss alone and being not
specific to RYGB, considering that our study did not include a control group with a bariatric
procedure without gastro-duodenal exclusion. To answer this question a future prospective
study including other bariatric procedures should be considered. Understanding the key
molecular changes that mediate the increased insulin sensitivity after bariatric procedures
may lead to novel non-surgical therapies for type II diabetes in the future.
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Free IGF-1 levels were determined in plasma collected from obese patients (Obese), patients
at least 12 months after RYGB, and non-obese controls (Lean). Data presented as mean ±
1SD.
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Relative Necdin and E2F4 RNA levels normalized to GAPDH RNA levels in subcutaneous
and omental adipose tissue collected from obese patients, patients at least 12 months after
RYGB, and non-obese controls. Data presented as mean ± SEM. * = P<0.05 vs. obese; ** =
P<0.01 vs. obese.
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Effect of des-IGF-1 on Necdin and E2F4 gene expression in cultured adipocytes. Data
presented as mean ± SEM. * = P<0.05 vs. control; ** = P<0.01 vs. control.
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Table1
Subject clinical characteristics
Variable Non-Obese Control Obese Post RYGB
n n=7 n=10 n=9
Gender (F/M) 3/4 7/3 8/1
BMI (kg/m2) 27.6 ± 2.8 49 ±1.2 25.6 ± 2.8
Age(years) 48 ±1.4 40 ± 9 41 ± 9
Values are mean ± SD.
Surg Obes Relat Dis. Author manuscript; available in PMC 2014 January 01.
